<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362244</url>
  </required_header>
  <id_info>
    <org_study_id>111782</org_study_id>
    <nct_id>NCT01362244</nct_id>
  </id_info>
  <brief_title>Mepolizumab in Nasal Polyposis</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-part, randomised, double-blind, placebo controlled, multi-centre study to investigate
      the use of mepolizumab (SB-240563) in reducing the need for surgery in subjects with severe
      bilateral nasal polyposis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasal polyposis has long been known as chronic inflammatory disease of the nasal mucosa. This
      disease is characterized by the presence of polyps in the upper nasal cavity, originating
      from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such
      as prominent nasal obstruction, post-nasal drip, loss of smell, and discharge. These symptoms
      can impact greatly upon a patient's quality of life.The etiology of nasal polyposis is
      currently unknown.

      The aim of this present study is to investigate the use of mepolizumab in reducing the
      potential need for surgery in subjects with severe bilateral nasal polyposis. The study is
      split into two parts: Part A is the treatment phase and focuses on the reduction of the need
      for surgery by exploring the efficacy of six doses of mepolizumab (one dose every four weeks)
      on nasal polyposis. This dosing regime will build upon the previous PoC study by exploring
      the potential for increased clinical efficacy as assessed by the potential need for surgery,
      and also and increased duration of action as assessed by time to relapse. Part B is the
      follow-up phase and will assess post-treatment nasal polyposis dynamics with a focus on time
      to relapse. All subjects participating in this study will undergo a run-in period on a low
      dose of intranasal steroids (INS) prior to first dosing. INS will be continued throughout the
      study up until study exit. This is to reflect the real life circumstances in which
      mepolizumab is intended to be used as a therapy. The overall aim of the study design is to
      further assess the impact in the potential need for surgery and explore an appropriate
      mepolizumab therapeutic regimen strategy for the treatment of nasal polyposis.

      In this study, the assessment of nasal polyposis will be performed by means of combining
      endoscopic polyp score with subject reported symptoms. This approach reflects real-life
      clinical assessment of nasal polyposis. Also, this study incorporates condition specific and
      general medical questionnaires in order to obtain a better understanding of the impact of
      severe nasal polyposis of the subject's quality of life (QOL). This is in line with
      increasing focus in the medical field on the effects of medical conditions and treatments on
      the quality of life of patients (Fokkens et al 2007).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2009</start_date>
  <completion_date type="Actual">December 5, 2014</completion_date>
  <primary_completion_date type="Actual">December 5, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduced Need for Surgery at the End of the Study (Week 25)</measure>
    <time_frame>Week 25</time_frame>
    <description>Assessment of the nasal polyposis condition was performed after six months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a visual analogue scale (VAS). Surgery was still deemed required for a participant with an ENP score of &gt;=3, or an ENP score of 2 and a VAS symptom score of &gt;7. The number of participants with reduced need for polyp surgery are presented as missing data set to non-responders (NR) and missing data last observation carry forward (LOCF). LOCF is defined as missing responses at Week 25 imputed with the last non-missing post-dose observation for that participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endoscopic Nasal Polyp (ENP) Score Dynamics at Screening and Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Screening; Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Each nostril was assessed for polyps and graded at Screening and at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. The ENP score ranges from 0 (no polyps) to 4, with a higher score indicating a larger polyp. The ENP score was recorded for both the right and the left nostril. The higher of the two scores was derived and used for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Polyp Surgery at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Assessment of the nasal polyposis condition was performed after 6 months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a VAS. Surgery was required for participants with ENP scores of &gt;=3, or ENP scores of 2 and a VAS symptom score of &gt;7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 2, 5, 9, 13, 21, and 25</measure>
    <time_frame>Baseline and Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>SBP and DBP were measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Pulse Rate at Weeks 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Baseline and Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Pulse rate was measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. Any abnormal clinically significant (CS) and not clinically significant (NCS) findings were identified. ECG abnormaility with respect to CS and NCS findings were judged by the investigator or appropriately qualified designee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of Clinical Chemistry Parameters Including Blood Urea Nitrogen (BUN), Glucose Fasting, Chloride, Sodium, Potassium, Carbon Dioxide, and Calcium at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>BUN, glucose fasting, chloride, sodium, potassium, carbon dioxide (CO2), and calcium were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Gamma Glutamyltransferase (GGT) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>ALT, AST, ALP, and GGT were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Clinical Chemistry Parameters of Albumin and Protein at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Albumin and protein were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Clinical Chemistry Parameters of Total and Direct Bilirubin, Creatinine (CRT), and Uric Acid (UA) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Total and direct bilirubin, creatinine, and uric acid were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Hematology Parameters of Platelet Count and White Blood Cell (WBC) Count, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Platelet count, WBC count, basophils, eosinophils, lymphocytes, monocytes, and neutrophils were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Hematology Parameters of Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Hemoglobin and MCHC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Hematology Parameter of Red Blood Cell (RBC) Count and Reticulocyte Count (RC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>RBC count and RC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Hematology Parameter of Mean Corpuscular Hemoglobin (MCH) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>MCH was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of the Hematology Parameter of Mean Corpuscular Volume (MCV) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>MCV was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value of the Hematology Parameter of Reticulocyte Count/Erythrocyte Uncorrected at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Reticulocyte count was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Clinically Relevant Urinalysis Results at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Specific gravity, power of hydrogen (pH), glucose, protein, blood, and ketones were assessed at Weeks (Wk) 1, 2, 5, 9, 13, 17, 21, and 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Treatment-emergent Adverse Event (AE) and Serious Adverse Event (SAE)</measure>
    <time_frame>Up to Week 25</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of the Forced Expiratory Volume in 1 Second (FEV1) at Weeks 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>FEV1 is defined as the volume of air forcefully expelled from the lungs in one second. FEV1 measurements were taken by spirometry at each clinic visit. FEV1 was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Forced Vital Capacity (FVC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>FVC is defined as the maximum amount of air that can forcibly be blown out after a maximum inspiration. FVC was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Peak Expiratory Flow Rate (PEFR) at Indicated Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>PEFR is defined as the maximum airflow generated during a forced expiration beginning with the lungs fully inflated. PEFR was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Symptoms Visual Analogue Scale (VAS) Scores at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Participants were asked to indicate on a VAS (0 to 10 centimeters) the severity of four nasal polyposis symptoms (one VAS for each symptom): rhinorrhea; mucus in the throat; nasal blockage; loss of smell. The left-hand side of the scale (0) represents &quot;not troublesome,&quot; and the right hand side of the scale (10) represents &quot;worst possible troublesome.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Peak Nasal Inspiratory Flow (PNIF) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Participants used a portable hand-held inspiratory flow meter to measure and record PNIF in the morning prior to taking the study medication. Three measurements were taken, and the largest measurement was recorded in the electronic diary. PNIF data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfaction Testing: Worst Nostril Score (WNS) and Mean Nostril Score (MNS) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
    <description>Sniffin'Sticks were used to assess each participant's sense of smell (olfaction). Olfaction testing results were recorded for both the right and left nostrils The worst nostril score (number of correct answers for the worst nostril) and the mean nostril score (mean number of correct answers across both nostrils) were recorded. Scores range from 0 to 12 (high score indicating normal olfactory sensation). Olfaction data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-Nasal Outcome Test (SNOT)-22 Questionnaire Total Score at Week 25 (Adjusted for Week 1 Baseline)</measure>
    <time_frame>Week 1 and Week 25</time_frame>
    <description>SNOT-22 questionnaire is a modification of the SNOT-20 and contains the questions (ques) related to smell and nasal obstruction. Each ques is graded with a numerical score for each response (res); scores range from 0 for &quot;no symptoms&quot; to 5 for &quot;as bad as things could be.&quot; Scores for each of the ques is summed to derive the total score for that par. at that visit. If the par. did not complete any ques at a visit, then he/she were not to have any missing values imputed, and his/her total score for that visit was set to missing. If a par. had some missing scores (but no more than 50% missing at that visit), then scores for the missing resp were imputed as the mean of the non-missing resp for that par. at that visit. The SNOT-22 total score ranges from 0 to 110, with higher scores representing a worse quality of life. Questionnaire data analysis was done using an ANCOVA to obtain the LS-means, treatment difference and confidence interval at Week 25, adjusting for Week 1 Baseline scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Score of the EuroQoL Quality of Life-5D (EQ-5D) Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</measure>
    <time_frame>Week 1 and Week 25</time_frame>
    <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The first part contains descriptions of the following five components: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to each of the five domains are measured on a 3-point scale (1-no problems, 2-some problems, and 3-severe problems). An index for the descriptive scores was derived using the general European weights, obtained for each of the countries in this study. Index scores were derived for each participant at each time point. ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score of the EQ-5D Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</measure>
    <time_frame>Week 1 and Week 25</time_frame>
    <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The second part of the questionnaire is a VAS question, requiring the participant to self rate his/her health score on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance at Weeks 1, 2, 5, 9, 13, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Blood samples were collected for the assessment of systemic clearance at Weeks 1, 2, 5, 9, 13, and 25. Systemic Clearance (CL) is estimated using a population-Pharmacokinetic model incorporating all available data points from all subjects. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Weeks 1, 2, 5, 9, 13, and 25</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Volume of distribution at steady-state was derived from pharmacokinetic parameter estimates of a population pharmacokinetic model. Blood samples were collected for analysis of volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. All available concentrations at all available datapoints from all participants were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bodyweight-adjusted Clearance</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Clearance is the volume of plasma that would contain the amount of drug excreted per day. Blood samples were collected for the assessment of bodyweight-adjusted clearance at Weeks 1, 2, 5, 9, 13, and 25. Clearance was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-State Volume of Distribution</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Steady-state volume of distribution is the blood and tissue volume into which a drug is distributed and the relative binding of drug to protein in these spaces. Blood samples were collected for the assessment of steady-state volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. Steady-state volume of distribution was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration (Cmax), Average Concentration (Cav[0-inf]), and Steady State Maximum Observed Plasma Drug Concentration (Cmax SS)</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Blood samples were collected for the assessment of Cmax, Cav(0-inf), and Cmax SS at Weeks 1, 2, 5, 9, 13, and 25. These parameters were estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Drug Concentration Versus Time Curve From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Blood samples were scheduled to be collected for the assessment of AUC(0-inf) at Weeks 1, 2, 5, 9, 13, and 25 AUC[0-inf] is derived from individual systemic clearance estimates using the expression AUC[0-inf] = Dose/CL. Hence all data are incorporated into the estimation of CL and by implication AUC[0-inf]. The actual time range over which pharmacokinetic data were collected was from time 0 to 336 days post first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (Alpha) and Half-life (Beta)</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
    <description>Half-life (Alpha) is the rate of decline in plasma concentrations due to the process of drug redistribution from the central to the peripheral compartment and half-life (Beta ) is the rate of decline due to the process of drug elimination due to metabolism. Blood samples were collected for the assessment of half-life (Alpha) and half-life (Beta) at Weeks 1, 2, 5, 9, 13, and 25. Half-life was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic/Pharmacodynamic (PK/PD) Model Derived Baseline</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
    <description>Blood samples were collected for the assessment of PK/PD model derived Baseline at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available blood eosinophil count data were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD Model Derived Coefficient of Variation of Baseline (CV[Baseline]), Variation of Maximal Effect of Drug (CV[Emax]), and Residual</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
    <description>A residual is the difference between the observed and predicted values. Blood samples were collected for the assessment of PK/PD model derived CV(Baseline), CV(Emax), and residual at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated subjects). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD Model Derived Half Maximal Effective Drug Concentration (EC50)</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
    <description>Blood samples were collected for the assessment of PK/PD model derived EC50 at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-partcipant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD Model Derived Maximum Inhibition</measure>
    <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
    <description>Blood samples were collected for the assessment of Maximum Inhibition at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Immunogenicity (Anti-mepolizumab Antibody Testing)</measure>
    <time_frame>Weeks 1, 5, 13, and 25</time_frame>
    <description>Blood samples were collected at Weeks 1, 5, 13, and 25 for anti-mepolizumab antibody testing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Treatment Periods 1-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Run In period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10-14 day run in period to assess the patients suitability for entry into Part A of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment periods 9-13</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>750 mg of mepolizumab by IV infusion</description>
    <arm_group_label>Treatment Periods 1-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by IV infusion</description>
    <arm_group_label>Treatment Periods 1-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Run In Medication</intervention_name>
    <description>subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).</description>
    <arm_group_label>Run In period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

        A subject will be eligible for inclusion in this study only if all of the following
        criteria apply:

          1. Subjects have a diagnosis of severe bilateral nasal polyposis at the screening visit
             and Visit 1 (i.e. at end of run-in period) which meets the definition of the situation
             indicative of the need for surgery as described in Decision Table 1 in Appendix 3.

          2. Subjects must have had at least one previous surgery for the removal of nasal polyps.

          3. Subjects must have an history of refractory response to steroid therapy as shown by
             being deemed potentially eligible for surgery despite having been on a
             regular/continuous course of nasal corticosteroids for the treatment of nasal
             polyposis for at least 3 months and/or have received a short course of oral steroids
             in the past for nasal polyp treatment.

          4. Male or female between 18 and 70 years of age, inclusive at time of signing informed
             consent.

          5. BMI within the range 19.0 to 31.0 kg/m2 (inclusive).

          6. Subjects must be free of any clinically significant disease that would interfere with
             the study schedule or procedures or compromise his/her safety.

          7. Subjects with concurrent asthma must be maintained on no more than 10mg/day of
             Prednisolone or the equivalent.

          8. Female subjects of childbearing potential must agree to use one of the contraception
             methods listed in Section 8.1. This criterion must be followed from 1 month prior to
             first dose of study medication until four months after last dose of study medication.

             Females of non -childbearing potential are defined as pre-menopausal females with a
             documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of
             spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose
             menopausal status is in doubt will be required to use one of the contraception methods
             in Section 8.1 if they wish to continue their HRT during the study (from 1 month prior
             to first dose of study medication until four months after last dose of study
             medication). Otherwise, they must discontinue HRT to allow confirmation of
             post-menopausal status prior to study enrollment. For most forms of HRT, at least 2- 4
             weeks will elapse between the cessation of therapy and the blood draw; this interval
             depends on the type and dosage of HRT. Following confirmation of their post-menopausal
             status, they can resume use of HRT during the study without use of a contraceptive
             method.

          9. Male subjects must agree to use one of the contraception methods listed in Section
             8.1. This criterion must be followed from the time of the first dose of study
             medication until four months after last dose of study medication.

         10. Subjects are capable of giving written informed consent, which includes agreeing to be
             compliant with the study requirements and restrictions listed in the consent form.

         11. Subjects are willing and available to complete the study and all measurements.

         12. Subjects are capable of reading, comprehending, and writing the local language at a
             sufficient level to complete study related materials.

        Exclusion:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          1. As a result of medical interview, physical examination, or screening investigation the
             physician responsible considers the subject unfit for the study.

          2. Subjects requiring oral corticosteroids at a dose greater than 10mg Prednisolone or
             equivalent during the study will be terminated from the study.

          3. Subjects who have had an asthma exacerbation requiring admission to hospital within 4
             weeks of Screening.

          4. Subjects who have received immunotherapy within the previous 12 months.

          5. Subjects with a positive pre-study drug/alcohol screen. A minimum list of drugs that
             will be screened for include amphetamines, barbiturates, cocaine, opiates,
             cannabinoids and benzodiazepines.

          6. Subjects with a known medical history of Hepatitis B, Hepatitis C, or HIV infection.

          7. Subjects with a history or suspicion of drug abuse or alcohol abuse within the last 6
             months.

          8. Subjects who are currently receiving, or have received within 3 months prior to first
             mepolizumab dose, chemotherapy, radiotherapy or investigational medications/therapies.

          9. Subjects with one or more of the following abnormal laboratory values:

               -  Serum creatinine ≥ 3 times institutional ULN

               -  AST or/ALT ≥ 5 times institutional ULN

               -  Platelet count &lt; 50,000/μL

         10. Subjects with a history of sensitivity to any of the study medications, or components
             thereof or a history of drug or other allergy that, in the opinion of the investigator
             or GSK Medical Monitor, contraindicates their participation. Aspirin-sensitive
             subjects are acceptable.

         11. Subjects with a history of allergic reaction to anti-IL-5 or other antibody therapy.

         12. Pregnant females as determined by positive serum pregnancy test at screening or
             positive urine pregnancy test prior to each dosing occasion.

         13. Breastfeeding/Lactating females.

         14. Subjects who currently smoke or have smoked in the last 6 months.

         15. Subjects who are unwilling or unable to follow the procedures outlined in the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>WC1X 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <results_first_submitted>November 23, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Intranasal Steroids</keyword>
  <keyword>Severe Nasal Polyposis</keyword>
  <keyword>Polyp Relapse</keyword>
  <keyword>Endoscopic Polyp Score</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111782</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At the end of a 10- to 14-day Run-in Period, participants (par.) were assessed for entry into the Treatment Period, comprised of 8 outpatient visits. For 6 of these visits, participants received a 4-weekly dose of either 750 milligrams (mg) mepolizumab or placebo. Four of the par. withdrew prior to 1st dose and are not included in the par. flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mepolizumab 750 mg</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Meet Continuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mepolizumab 750 mg</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="10.73"/>
                    <measurement group_id="B2" value="49.7" spread="10.38"/>
                    <measurement group_id="B3" value="50.2" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Central/South Asian Heritage (Htg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese/East Asian Heritage/ South East Asian Htg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduced Need for Surgery at the End of the Study (Week 25)</title>
        <description>Assessment of the nasal polyposis condition was performed after six months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a visual analogue scale (VAS). Surgery was still deemed required for a participant with an ENP score of &gt;=3, or an ENP score of 2 and a VAS symptom score of &gt;7. The number of participants with reduced need for polyp surgery are presented as missing data set to non-responders (NR) and missing data last observation carry forward (LOCF). LOCF is defined as missing responses at Week 25 imputed with the last non-missing post-dose observation for that participant.</description>
        <time_frame>Week 25</time_frame>
        <population>Per Protocol Population: all randomized participants who received at least one dose of study treatment and who complied with the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduced Need for Surgery at the End of the Study (Week 25)</title>
          <description>Assessment of the nasal polyposis condition was performed after six months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a visual analogue scale (VAS). Surgery was still deemed required for a participant with an ENP score of &gt;=3, or an ENP score of 2 and a VAS symptom score of &gt;7. The number of participants with reduced need for polyp surgery are presented as missing data set to non-responders (NR) and missing data last observation carry forward (LOCF). LOCF is defined as missing responses at Week 25 imputed with the last non-missing post-dose observation for that participant.</description>
          <population>Per Protocol Population: all randomized participants who received at least one dose of study treatment and who complied with the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NR, Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NR, Non-Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCF, Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCF, Non- Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical data is presented for NR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical data is presented for LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endoscopic Nasal Polyp (ENP) Score Dynamics at Screening and Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Each nostril was assessed for polyps and graded at Screening and at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. The ENP score ranges from 0 (no polyps) to 4, with a higher score indicating a larger polyp. The ENP score was recorded for both the right and the left nostril. The higher of the two scores was derived and used for the analysis.</description>
        <time_frame>Screening; Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>PP Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endoscopic Nasal Polyp (ENP) Score Dynamics at Screening and Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Each nostril was assessed for polyps and graded at Screening and at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. The ENP score ranges from 0 (no polyps) to 4, with a higher score indicating a larger polyp. The ENP score was recorded for both the right and the left nostril. The higher of the two scores was derived and used for the analysis.</description>
          <population>PP Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, ENP score 0, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, ENP score 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, ENP score 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, ENP score &gt;=3, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, ENP score 0, n=48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, ENP score 1, n=48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, ENP score 2, n=48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, ENP score &gt;=3, n=48, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, ENP score 0, n=49, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, ENP score 1, n=49, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, ENP score 2, n=49, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, ENP score &gt;=3, n=49, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, ENP score 0, n=49, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, ENP score 1, n=49, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, ENP score 2, n=49, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, ENP score &gt;=3, n=49, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, ENP score 0, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, ENP score 1, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, ENP score 2, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, ENP score &gt;=3, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, ENP score 0, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, ENP score 1, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, ENP score 2, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, ENP score &gt;=3, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, ENP score 0, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, ENP score 1, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, ENP score 2, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, ENP score &gt;=3, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, ENP score 0, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, ENP score 1, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, ENP score 2, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, ENP score &gt;=3, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
            <estimate_desc>Week 1</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>6.85</ci_upper_limit>
            <estimate_desc>Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>4.49</ci_upper_limit>
            <estimate_desc>Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>18.94</ci_upper_limit>
            <estimate_desc>Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.18</ci_lower_limit>
            <ci_upper_limit>62.19</ci_upper_limit>
            <estimate_desc>Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.223</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>13.90</ci_upper_limit>
            <estimate_desc>Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>30.66</ci_upper_limit>
            <estimate_desc>Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>28.42</ci_upper_limit>
            <estimate_desc>Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Polyp Surgery at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Assessment of the nasal polyposis condition was performed after 6 months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a VAS. Surgery was required for participants with ENP scores of &gt;=3, or ENP scores of 2 and a VAS symptom score of &gt;7.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Polyp Surgery at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Assessment of the nasal polyposis condition was performed after 6 months of dosing to determine the situation indicative of a reduction in the need for surgery. The components used to determine the need for surgery were endoscopic polyp scores and a severity of condition as measured by a VAS. Surgery was required for participants with ENP scores of &gt;=3, or ENP scores of 2 and a VAS symptom score of &gt;7.</description>
          <population>PP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 2, 5, 9, 13, 21, and 25</title>
        <description>SBP and DBP were measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
        <time_frame>Baseline and Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population: participants who received &gt;=1 dose of study treatment (based on actual treatment received). A participant randomized to mepolizumab took placebo in error. Thus, “N” for the placebo arm of the SP is greater than for the ITT Population. Participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 2, 5, 9, 13, 21, and 25</title>
          <description>SBP and DBP were measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
          <population>Safety Population: participants who received &gt;=1 dose of study treatment (based on actual treatment received). A participant randomized to mepolizumab took placebo in error. Thus, “N” for the placebo arm of the SP is greater than for the ITT Population. Participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="14.14"/>
                    <measurement group_id="O2" value="4.6" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 5, n=53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="11.74"/>
                    <measurement group_id="O2" value="0.5" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 9, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="15.01"/>
                    <measurement group_id="O2" value="1.0" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 13, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="12.17"/>
                    <measurement group_id="O2" value="0.9" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 17, n=45, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="13.15"/>
                    <measurement group_id="O2" value="0.3" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="14.55"/>
                    <measurement group_id="O2" value="-1.7" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="15.47"/>
                    <measurement group_id="O2" value="-1.8" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="7.97"/>
                    <measurement group_id="O2" value="-0.9" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 5, n=53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="8.56"/>
                    <measurement group_id="O2" value="-0.1" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 9, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="12.05"/>
                    <measurement group_id="O2" value="0.0" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 13, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="9.99"/>
                    <measurement group_id="O2" value="-0.5" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 17, n=45, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="8.90"/>
                    <measurement group_id="O2" value="-0.4" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.95"/>
                    <measurement group_id="O2" value="-1.5" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="10.27"/>
                    <measurement group_id="O2" value="-2.2" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Pulse Rate at Weeks 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Pulse rate was measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
        <time_frame>Baseline and Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Pulse Rate at Weeks 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Pulse rate was measured at Baseline (Week 1) and at Weeks 2, 5, 9, 13, 17, 21, and 25. Baseline is defined as the Week 1 pre-dose assessment. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="8.88"/>
                    <measurement group_id="O2" value="0.0" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="9.09"/>
                    <measurement group_id="O2" value="-1.0" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="8.40"/>
                    <measurement group_id="O2" value="-0.8" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.05"/>
                    <measurement group_id="O2" value="-2.4" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, n=45, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="9.71"/>
                    <measurement group_id="O2" value="-0.6" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, n=41, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="9.56"/>
                    <measurement group_id="O2" value="-1.2" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="9.29"/>
                    <measurement group_id="O2" value="0.0" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. Any abnormal clinically significant (CS) and not clinically significant (NCS) findings were identified. ECG abnormaility with respect to CS and NCS findings were judged by the investigator or appropriately qualified designee.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. Any abnormal clinically significant (CS) and not clinically significant (NCS) findings were identified. ECG abnormaility with respect to CS and NCS findings were judged by the investigator or appropriately qualified designee.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, NCS, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, CS, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, NCS, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, CS, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, NCS, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, CS, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, NCS, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, CS, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, NCS, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, CS, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, NCS, n=45, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, CS, n=45, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, NCS, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, CS, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, NCS, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, CS, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of Clinical Chemistry Parameters Including Blood Urea Nitrogen (BUN), Glucose Fasting, Chloride, Sodium, Potassium, Carbon Dioxide, and Calcium at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>BUN, glucose fasting, chloride, sodium, potassium, carbon dioxide (CO2), and calcium were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of Clinical Chemistry Parameters Including Blood Urea Nitrogen (BUN), Glucose Fasting, Chloride, Sodium, Potassium, Carbon Dioxide, and Calcium at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>BUN, glucose fasting, chloride, sodium, potassium, carbon dioxide (CO2), and calcium were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, Week 1, pre-dose, n=46, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33529" spread="0.07920"/>
                    <measurement group_id="O2" value="2.31724" spread="0.08132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34262" spread="0.07908"/>
                    <measurement group_id="O2" value="2.35237" spread="0.09561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 5, pre-dose, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31874" spread="0.09841"/>
                    <measurement group_id="O2" value="2.34182" spread="0.09948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 9, pre-dose, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31885" spread="0.07624"/>
                    <measurement group_id="O2" value="2.36803" spread="0.18232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 13, pre-dose, n=44, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32566" spread="0.07731"/>
                    <measurement group_id="O2" value="2.34848" spread="0.08552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31207" spread="0.09495"/>
                    <measurement group_id="O2" value="2.35610" spread="0.10049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30473" spread="0.08874"/>
                    <measurement group_id="O2" value="2.32699" spread="0.10993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31374" spread="0.13942"/>
                    <measurement group_id="O2" value="2.36884" spread="0.08507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 1, pre-dose, n=50, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.7" spread="2.57"/>
                    <measurement group_id="O2" value="103.8" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 2, n=50, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="2.23"/>
                    <measurement group_id="O2" value="103.5" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 5, pre-dose, n=51, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" spread="3.24"/>
                    <measurement group_id="O2" value="103.6" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 9, pre-dose, n=51, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.7" spread="2.85"/>
                    <measurement group_id="O2" value="103.6" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.4" spread="2.36"/>
                    <measurement group_id="O2" value="103.2" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 17, pre-dose, n=45, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.6" spread="2.72"/>
                    <measurement group_id="O2" value="103.4" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.6" spread="2.55"/>
                    <measurement group_id="O2" value="103.4" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 25, 4 weeks post last dose, n=40,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.0" spread="2.36"/>
                    <measurement group_id="O2" value="103.2" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 1, pre-dose, n=47, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="2.38"/>
                    <measurement group_id="O2" value="26.4" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 2, n=50, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="2.71"/>
                    <measurement group_id="O2" value="26.4" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 5, pre-dose, n=50, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="2.76"/>
                    <measurement group_id="O2" value="26.1" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="2.63"/>
                    <measurement group_id="O2" value="26.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 13, pre-dose, n=45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="2.32"/>
                    <measurement group_id="O2" value="26.4" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 17, pre-dose, n=45, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="2.98"/>
                    <measurement group_id="O2" value="26.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 21, pre-dose, n=40, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="2.05"/>
                    <measurement group_id="O2" value="26.4" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="2.73"/>
                    <measurement group_id="O2" value="27.0" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 1, pre-dose, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02333" spread="1.06419"/>
                    <measurement group_id="O2" value="4.90943" spread="0.55713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 2, n=49, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07525" spread="0.94855"/>
                    <measurement group_id="O2" value="4.85985" spread="0.69818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 5, pre-dose, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97329" spread="0.75574"/>
                    <measurement group_id="O2" value="0.75574" spread="0.68857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 9, pre-dose, n=50, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07978" spread="0.82661"/>
                    <measurement group_id="O2" value="5.01449" spread="0.70049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09957" spread="0.90555"/>
                    <measurement group_id="O2" value="4.95848" spread="0.63337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 17, pre-dose, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19291" spread="1.20604"/>
                    <measurement group_id="O2" value="4.99349" spread="0.65387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 21, pre-dose, n=40, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12557" spread="1.14974"/>
                    <measurement group_id="O2" value="5.01559" spread="0.55765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 25, 4 weeks post last dose, n=40, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31222" spread="1.55173"/>
                    <measurement group_id="O2" value="5.08589" spread="0.57875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.352"/>
                    <measurement group_id="O2" value="4.17" spread="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.345"/>
                    <measurement group_id="O2" value="4.23" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 5, pre-dose, n=51, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="0.420"/>
                    <measurement group_id="O2" value="4.15" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 9, pre-dose, n=52, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="0.364"/>
                    <measurement group_id="O2" value="4.19" spread="0.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="0.325"/>
                    <measurement group_id="O2" value="4.19" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 17, pre-dose, n=44, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="0.389"/>
                    <measurement group_id="O2" value="4.28" spread="0.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 21, pre-dose, n=40, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="0.428"/>
                    <measurement group_id="O2" value="4.27" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 25,4 weeks post last dose, n=41,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="0.404"/>
                    <measurement group_id="O2" value="4.29" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.9" spread="2.15"/>
                    <measurement group_id="O2" value="141.7" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.1" spread="1.95"/>
                    <measurement group_id="O2" value="141.5" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 5, pre-dose, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.7" spread="2.16"/>
                    <measurement group_id="O2" value="141.7" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 9, pre-dose, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.0" spread="2.27"/>
                    <measurement group_id="O2" value="141.5" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" spread="1.93"/>
                    <measurement group_id="O2" value="141.4" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.6" spread="2.34"/>
                    <measurement group_id="O2" value="141.5" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.5" spread="2.04"/>
                    <measurement group_id="O2" value="141.6" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.4" spread="2.11"/>
                    <measurement group_id="O2" value="141.7" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 1, pre-dose, n=51, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6929" spread="3.69770"/>
                    <measurement group_id="O2" value="7.1568" spread="3.35084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 2, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8847" spread="3.86054"/>
                    <measurement group_id="O2" value="7.1870" spread="3.81593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 5, pre-dose, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9122" spread="3.86267"/>
                    <measurement group_id="O2" value="7.2488" spread="4.02159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5806" spread="3.77958"/>
                    <measurement group_id="O2" value="7.0658" spread="3.40683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4124" spread="3.50688"/>
                    <measurement group_id="O2" value="7.5311" spread="3.68104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3499" spread="3.61940"/>
                    <measurement group_id="O2" value="7.9377" spread="3.59500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7361" spread="3.58351"/>
                    <measurement group_id="O2" value="7.2357" spread="3.21507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8770" spread="3.86299"/>
                    <measurement group_id="O2" value="6.9864" spread="3.01889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Gamma Glutamyltransferase (GGT) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>ALT, AST, ALP, and GGT were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Gamma Glutamyltransferase (GGT) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>ALT, AST, ALP, and GGT were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="17.09"/>
                    <measurement group_id="O2" value="67.8" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="15.92"/>
                    <measurement group_id="O2" value="69.0" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 5, pre-dose, n=51, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="17.31"/>
                    <measurement group_id="O2" value="68.5" spread="21.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="17.63"/>
                    <measurement group_id="O2" value="69.8" spread="20.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="16.92"/>
                    <measurement group_id="O2" value="69.7" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="16.30"/>
                    <measurement group_id="O2" value="69.5" spread="19.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 21, pre-dose, n=41, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="14.75"/>
                    <measurement group_id="O2" value="70.4" spread="21.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="14.56"/>
                    <measurement group_id="O2" value="72.4" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="13.33"/>
                    <measurement group_id="O2" value="26.1" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="11.60"/>
                    <measurement group_id="O2" value="26.9" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 5, pre-dose, n=51, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="15.11"/>
                    <measurement group_id="O2" value="25.0" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 9, pre-dose, n=52, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="10.78"/>
                    <measurement group_id="O2" value="24.7" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="18.21"/>
                    <measurement group_id="O2" value="25.2" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="11.98"/>
                    <measurement group_id="O2" value="27.1" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="14.32"/>
                    <measurement group_id="O2" value="27.6" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="15.43"/>
                    <measurement group_id="O2" value="26.4" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="7.73"/>
                    <measurement group_id="O2" value="25.5" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 2, n=51, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="5.54"/>
                    <measurement group_id="O2" value="24.3" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 5, pre-dose, n=51, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="6.51"/>
                    <measurement group_id="O2" value="23.6" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="6.06"/>
                    <measurement group_id="O2" value="23.6" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="6.86"/>
                    <measurement group_id="O2" value="23.9" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 17, pre-dose, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="8.34"/>
                    <measurement group_id="O2" value="23.9" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 21, pre-dose, n=40, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="6.20"/>
                    <measurement group_id="O2" value="23.8" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="5.63"/>
                    <measurement group_id="O2" value="24.0" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 1, pre-dose, n=50, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="49.18"/>
                    <measurement group_id="O2" value="26.6" spread="20.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="46.31"/>
                    <measurement group_id="O2" value="28.3" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 5, pre-dose, n=50, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="59.91"/>
                    <measurement group_id="O2" value="28.0" spread="25.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 9, pre-dose, n=50, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="41.07"/>
                    <measurement group_id="O2" value="29.5" spread="24.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="69.60"/>
                    <measurement group_id="O2" value="29.2" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 17, pre-dose, n=44,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="57.83"/>
                    <measurement group_id="O2" value="34.6" spread="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 21, pre-dose, n=41, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="78.78"/>
                    <measurement group_id="O2" value="32.9" spread="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="54.09"/>
                    <measurement group_id="O2" value="28.4" spread="17.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Clinical Chemistry Parameters of Albumin and Protein at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Albumin and protein were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Clinical Chemistry Parameters of Albumin and Protein at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Albumin and protein were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="3.00"/>
                    <measurement group_id="O2" value="46.1" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="2.74"/>
                    <measurement group_id="O2" value="46.3" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 5, pre-dose, n=52, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="2.46"/>
                    <measurement group_id="O2" value="45.8" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 9, pre-dose, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="2.71"/>
                    <measurement group_id="O2" value="45.2" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="2.26"/>
                    <measurement group_id="O2" value="45.8" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 17, pre-dose, n=44, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="2.45"/>
                    <measurement group_id="O2" value="45.6" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="2.69"/>
                    <measurement group_id="O2" value="45.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="2.55"/>
                    <measurement group_id="O2" value="45.3" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 1, pre-dose, n=50, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="5.09"/>
                    <measurement group_id="O2" value="73.7" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 2, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="5.27"/>
                    <measurement group_id="O2" value="73.7" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 5, pre-dose, n=50, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="5.33"/>
                    <measurement group_id="O2" value="72.6" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="5.39"/>
                    <measurement group_id="O2" value="72.6" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 13, pre-dose, n=44, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="4.76"/>
                    <measurement group_id="O2" value="72.8" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="4.08"/>
                    <measurement group_id="O2" value="72.1" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="4.30"/>
                    <measurement group_id="O2" value="71.4" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="4.41"/>
                    <measurement group_id="O2" value="71.7" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Clinical Chemistry Parameters of Total and Direct Bilirubin, Creatinine (CRT), and Uric Acid (UA) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Total and direct bilirubin, creatinine, and uric acid were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Clinical Chemistry Parameters of Total and Direct Bilirubin, Creatinine (CRT), and Uric Acid (UA) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Total and direct bilirubin, creatinine, and uric acid were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UA, Week 1, pre-dose, n=48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6280.75" spread="40503.47"/>
                    <measurement group_id="O2" value="9943.59" spread="47675.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 2, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7734.39" spread="50942.24"/>
                    <measurement group_id="O2" value="10906.56" spread="51211.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 5, pre-dose, n=50, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12991.02" spread="65048.95"/>
                    <measurement group_id="O2" value="13352.52" spread="64149.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 9, pre-dose, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13147.62" spread="62976.19"/>
                    <measurement group_id="O2" value="24031.30" spread="90312.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14802.92" spread="69028.68"/>
                    <measurement group_id="O2" value="25208.07" spread="90067.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15378.37" spread="70783.69"/>
                    <measurement group_id="O2" value="21723.77" spread="89724.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 21, pre-dose, n=40, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10414.21" spread="63827.10"/>
                    <measurement group_id="O2" value="22994.49" spread="94463.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UA, Week 25, 4 weeks post last dose, n=40, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9602.10" spread="58607.26"/>
                    <measurement group_id="O2" value="24506.63" spread="96050.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2445" spread="15.71113"/>
                    <measurement group_id="O2" value="77.5162" spread="14.87768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5450" spread="14.66619"/>
                    <measurement group_id="O2" value="78.3620" spread="13.55791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 5, pre-dose, n=52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0978" spread="14.80378"/>
                    <measurement group_id="O2" value="77.7282" spread="13.97357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 9, pre-dose, n=52, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0171" spread="15.27077"/>
                    <measurement group_id="O2" value="75.9868" spread="13.78284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5454" spread="17.47683"/>
                    <measurement group_id="O2" value="77.5522" spread="13.18623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5074" spread="17.96973"/>
                    <measurement group_id="O2" value="76.7809" spread="12.15771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8093" spread="17.58041"/>
                    <measurement group_id="O2" value="75.1511" spread="11.77313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRT, Week 25,4 weeks post last dose,n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9687" spread="17.48642"/>
                    <measurement group_id="O2" value="77.7839" spread="12.25219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.878" spread="3.2705"/>
                    <measurement group_id="O2" value="10.595" spread="6.2074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.016" spread="4.5747"/>
                    <measurement group_id="O2" value="10.520" spread="4.1684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 5, pre-dose, n=51, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.189" spread="4.0635"/>
                    <measurement group_id="O2" value="10.878" spread="4.4865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 5, 4-6 months, n=0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed for this parameter at this time point</measurement>
                    <measurement group_id="O2" value="7.000">A standard deviation was not calculated for the single participant analyzed for this parameter at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.145" spread="3.5212"/>
                    <measurement group_id="O2" value="10.484" spread="4.2254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.918" spread="3.6143"/>
                    <measurement group_id="O2" value="10.012" spread="5.0501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 17, pre-dose, n=44, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.624" spread="4.0522"/>
                    <measurement group_id="O2" value="9.877" spread="4.6822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 17, 4-6 months, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.000" spread="2.8284"/>
                    <measurement group_id="O2" value="7.775" spread="1.0960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 21, pre-dose, n=40, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.266" spread="3.6078"/>
                    <measurement group_id="O2" value="10.622" spread="6.0172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 21, 4-6 months, n=0, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed for this parameter at this time point</measurement>
                    <measurement group_id="O2" value="7.850" spread="1.6179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.820" spread="3.0792"/>
                    <measurement group_id="O2" value="10.162" spread="6.3294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 1, pre-dose, n=50, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6685" spread="0.91566"/>
                    <measurement group_id="O2" value="2.8818" spread="1.54541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9160" spread="1.02560"/>
                    <measurement group_id="O2" value="3.0690" spread="1.25759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 5, pre-dose, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7981" spread="0.90148"/>
                    <measurement group_id="O2" value="0.90148" spread="1.12944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 5, 4-6 months, n=0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed for this parameter at this time point</measurement>
                    <measurement group_id="O2" value="3.0000">A standard deviation was not calculated for the single participant analyzed for this parameter at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 9, pre-dose, n=51, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9203" spread="1.10282"/>
                    <measurement group_id="O2" value="2.9693" spread="1.03703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 13, pre-dose, n=43, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7958" spread="0.82254"/>
                    <measurement group_id="O2" value="3.0299" spread="1.55388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 17, pre-dose, n=43, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9931" spread="0.85581"/>
                    <measurement group_id="O2" value="2.8714" spread="1.18421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 17, 4-6 months, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9995" spread="0.00071"/>
                    <measurement group_id="O2" value="2.1970" spread="0.27860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 21, pre-dose, n=39, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9267" spread="0.98861"/>
                    <measurement group_id="O2" value="3.0561" spread="1.33234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 21, 4-6 months, n=0, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed for this parameter at this time point</measurement>
                    <measurement group_id="O2" value="2.5783" spread="0.51879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0011" spread="0.95645"/>
                    <measurement group_id="O2" value="2.9864" spread="1.42919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Hematology Parameters of Platelet Count and White Blood Cell (WBC) Count, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Platelet count, WBC count, basophils, eosinophils, lymphocytes, monocytes, and neutrophils were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Hematology Parameters of Platelet Count and White Blood Cell (WBC) Count, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Platelet count, WBC count, basophils, eosinophils, lymphocytes, monocytes, and neutrophils were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.1" spread="45.91"/>
                    <measurement group_id="O2" value="262.9" spread="53.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.1" spread="47.25"/>
                    <measurement group_id="O2" value="264.6" spread="56.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.7" spread="46.67"/>
                    <measurement group_id="O2" value="266.4" spread="61.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.1" spread="43.29"/>
                    <measurement group_id="O2" value="267.0" spread="57.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.7" spread="53.68"/>
                    <measurement group_id="O2" value="273.2" spread="56.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.4" spread="45.59"/>
                    <measurement group_id="O2" value="270.2" spread="52.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.0" spread="44.39"/>
                    <measurement group_id="O2" value="271.2" spread="53.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet, Week 25, 4 weeks post last dose, n=41,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.1" spread="48.64"/>
                    <measurement group_id="O2" value="279.3" spread="60.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="1.794"/>
                    <measurement group_id="O2" value="6.81" spread="1.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" spread="1.535"/>
                    <measurement group_id="O2" value="6.90" spread="2.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="1.580"/>
                    <measurement group_id="O2" value="6.77" spread="1.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.90" spread="1.508"/>
                    <measurement group_id="O2" value="6.92" spread="1.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.541"/>
                    <measurement group_id="O2" value="7.18" spread="2.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" spread="1.780"/>
                    <measurement group_id="O2" value="6.99" spread="1.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="1.143"/>
                    <measurement group_id="O2" value="6.92" spread="1.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 25, 4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.357"/>
                    <measurement group_id="O2" value="7.00" spread="1.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.029"/>
                    <measurement group_id="O2" value="0.05" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 2, n=53, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.021"/>
                    <measurement group_id="O2" value="0.05" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.013"/>
                    <measurement group_id="O2" value="0.05" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.017"/>
                    <measurement group_id="O2" value="0.05" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.024"/>
                    <measurement group_id="O2" value="0.06" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.021"/>
                    <measurement group_id="O2" value="0.05" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.021"/>
                    <measurement group_id="O2" value="0.05" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophil, Week 25, 4 weeks post last dose, n=41,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.021"/>
                    <measurement group_id="O2" value="0.05" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.496"/>
                    <measurement group_id="O2" value="0.54" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.079"/>
                    <measurement group_id="O2" value="0.55" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.030"/>
                    <measurement group_id="O2" value="0.51" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.027"/>
                    <measurement group_id="O2" value="0.55" spread="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.196"/>
                    <measurement group_id="O2" value="0.56" spread="0.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.125"/>
                    <measurement group_id="O2" value="0.45" spread="0.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.023"/>
                    <measurement group_id="O2" value="0.49" spread="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil, Week 25,4 weeks post last dose,n=41,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.029"/>
                    <measurement group_id="O2" value="0.44" spread="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.568"/>
                    <measurement group_id="O2" value="1.99" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.531"/>
                    <measurement group_id="O2" value="1.96" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.635"/>
                    <measurement group_id="O2" value="1.90" spread="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.596"/>
                    <measurement group_id="O2" value="2.03" spread="0.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.457"/>
                    <measurement group_id="O2" value="2.02" spread="0.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.466"/>
                    <measurement group_id="O2" value="1.92" spread="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.541"/>
                    <measurement group_id="O2" value="1.98" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte, Week 25,4 weeks post last dose,n=41, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.604"/>
                    <measurement group_id="O2" value="1.91" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 1, pre-dose, n=52, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.166"/>
                    <measurement group_id="O2" value="0.50" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.175"/>
                    <measurement group_id="O2" value="0.54" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.170"/>
                    <measurement group_id="O2" value="0.51" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.140"/>
                    <measurement group_id="O2" value="0.53" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.188"/>
                    <measurement group_id="O2" value="0.55" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.172"/>
                    <measurement group_id="O2" value="0.52" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.150"/>
                    <measurement group_id="O2" value="0.55" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 25,4 weeks post last dose,n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.130"/>
                    <measurement group_id="O2" value="0.57" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96481" spread="1.374461"/>
                    <measurement group_id="O2" value="3.72673" spread="1.085727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65642" spread="1.295348"/>
                    <measurement group_id="O2" value="3.80635" spread="1.525888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73509" spread="1.238233"/>
                    <measurement group_id="O2" value="3.78720" spread="1.237163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 9, pre-dose, n=51, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49333" spread="1.160355"/>
                    <measurement group_id="O2" value="3.76333" spread="1.095441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 13, pre-dose, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52400" spread="1.287322"/>
                    <measurement group_id="O2" value="3.96169" spread="1.563461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65711" spread="1.624295"/>
                    <measurement group_id="O2" value="4.06657" spread="1.550068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45738" spread="0.907831"/>
                    <measurement group_id="O2" value="3.83824" spread="1.137039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophil, Week 25,4 weeks post last dose,n=41, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46854" spread="1.045869"/>
                    <measurement group_id="O2" value="4.03125" spread="1.452175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Hematology Parameters of Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Hemoglobin and MCHC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Hematology Parameters of Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Hemoglobin and MCHC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, Week 1, pre-dose, n=51, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.445" spread="11.5174"/>
                    <measurement group_id="O2" value="145.566" spread="22.1192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.013" spread="12.2563"/>
                    <measurement group_id="O2" value="147.625" spread="11.1436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.955" spread="10.8860"/>
                    <measurement group_id="O2" value="146.071" spread="12.7175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.135" spread="11.0248"/>
                    <measurement group_id="O2" value="146.252" spread="12.0539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.498" spread="10.9510"/>
                    <measurement group_id="O2" value="147.427" spread="11.9305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.988" spread="11.4327"/>
                    <measurement group_id="O2" value="148.045" spread="12.0595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.597" spread="11.8831"/>
                    <measurement group_id="O2" value="146.953" spread="10.9213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Week 25,4 weeks post last dose,n=41, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.927" spread="10.5835"/>
                    <measurement group_id="O2" value="147.940" spread="8.9890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 1, pre-dose, n=52, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.3" spread="8.71"/>
                    <measurement group_id="O2" value="338.6" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 2, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.1" spread="10.34"/>
                    <measurement group_id="O2" value="335.2" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.1" spread="7.71"/>
                    <measurement group_id="O2" value="338.6" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.5" spread="10.40"/>
                    <measurement group_id="O2" value="337.7" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 13, pre-dose, n=44, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.7" spread="9.52"/>
                    <measurement group_id="O2" value="339.6" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.6" spread="9.56"/>
                    <measurement group_id="O2" value="337.0" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.9" spread="9.35"/>
                    <measurement group_id="O2" value="336.4" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Week 25,4 weeks post last dose,n=40, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.9" spread="9.23"/>
                    <measurement group_id="O2" value="339.3" spread="18.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Hematology Parameter of Red Blood Cell (RBC) Count and Reticulocyte Count (RC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>RBC count and RC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Hematology Parameter of Red Blood Cell (RBC) Count and Reticulocyte Count (RC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>RBC count and RC were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>10^12 cells per litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC, Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.889" spread="0.3758"/>
                    <measurement group_id="O2" value="4.930" spread="0.4830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.868" spread="0.4024"/>
                    <measurement group_id="O2" value="4.937" spread="0.4340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.876" spread="0.3494"/>
                    <measurement group_id="O2" value="4.867" spread="0.5115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.875" spread="0.3792"/>
                    <measurement group_id="O2" value="4.879" spread="0.4758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.889" spread="0.3511"/>
                    <measurement group_id="O2" value="4.923" spread="0.4828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.824" spread="0.3735"/>
                    <measurement group_id="O2" value="4.938" spread="0.5058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.840" spread="0.3743"/>
                    <measurement group_id="O2" value="4.910" spread="0.5165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Week 25,4 weeks post last dose,n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.902" spread="0.3551"/>
                    <measurement group_id="O2" value="4.901" spread="0.3343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 1, pre-dose, n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0537" spread="0.01651"/>
                    <measurement group_id="O2" value="0.0495" spread="0.01666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 2, n=33, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0495" spread="0.01682"/>
                    <measurement group_id="O2" value="0.0506" spread="0.01879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 5, pre-dose, n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0461" spread="0.01416"/>
                    <measurement group_id="O2" value="0.0496" spread="0.02530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 9, pre-dose, n=29, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0443" spread="0.01327"/>
                    <measurement group_id="O2" value="0.0513" spread="0.02581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 13, pre-dose, n=28, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0473" spread="0.01530"/>
                    <measurement group_id="O2" value="0.0528" spread="0.01780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 17, pre-dose, n=28, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0482" spread="0.01604"/>
                    <measurement group_id="O2" value="0.0493" spread="0.01847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 21, pre-dose, n=26, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0459" spread="0.01592"/>
                    <measurement group_id="O2" value="0.0521" spread="0.01594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC, Week 25,4 weeks post last dose,n=24, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0489" spread="0.01640"/>
                    <measurement group_id="O2" value="0.0580" spread="0.02625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Hematology Parameter of Mean Corpuscular Hemoglobin (MCH) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>MCH was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Hematology Parameter of Mean Corpuscular Hemoglobin (MCH) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>MCH was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Picograms (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, pre-dose, n=52, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.44" spread="1.215"/>
                    <measurement group_id="O2" value="30.26" spread="1.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.46" spread="1.359"/>
                    <measurement group_id="O2" value="29.94" spread="1.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.37" spread="1.301"/>
                    <measurement group_id="O2" value="30.10" spread="1.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.23" spread="1.378"/>
                    <measurement group_id="O2" value="30.07" spread="1.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, pre-dose, n=44, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.22" spread="1.292"/>
                    <measurement group_id="O2" value="29.94" spread="2.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.29" spread="1.339"/>
                    <measurement group_id="O2" value="30.10" spread="1.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.33" spread="1.354"/>
                    <measurement group_id="O2" value="30.00" spread="2.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25,4 weeks post last dose,n=40, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.41" spread="1.196"/>
                    <measurement group_id="O2" value="30.26" spread="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of the Hematology Parameter of Mean Corpuscular Volume (MCV) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>MCV was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of the Hematology Parameter of Mean Corpuscular Volume (MCV) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>MCV was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, pre-dose, n=52, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.04" spread="3.850"/>
                    <measurement group_id="O2" value="89.43" spread="5.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.06" spread="3.997"/>
                    <measurement group_id="O2" value="89.41" spread="4.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.85" spread="3.911"/>
                    <measurement group_id="O2" value="89.38" spread="4.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, pre-dose, n=51, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.81" spread="3.897"/>
                    <measurement group_id="O2" value="89.07" spread="5.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.19" spread="3.934"/>
                    <measurement group_id="O2" value="89.12" spread="5.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, pre-dose, n=45, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.50" spread="3.714"/>
                    <measurement group_id="O2" value="89.33" spread="5.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, pre-dose, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.46" spread="3.673"/>
                    <measurement group_id="O2" value="89.23" spread="5.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25,4 weeks post last dose, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.68" spread="3.364"/>
                    <measurement group_id="O2" value="89.91" spread="3.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Value of the Hematology Parameter of Reticulocyte Count/Erythrocyte Uncorrected at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Reticulocyte count was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Value of the Hematology Parameter of Reticulocyte Count/Erythrocyte Uncorrected at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Reticulocyte count was assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Safety Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Fraction of 1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, pre-dose, n=19, 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1723" spread="0.16091"/>
                    <measurement group_id="O2" value="0.1053" spread="0.05750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=19, 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1710" spread="0.15032"/>
                    <measurement group_id="O2" value="0.1271" spread="0.09305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, pre-dose, n=19, 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1731" spread="0.16016"/>
                    <measurement group_id="O2" value="0.1464" spread="0.13471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, pre-dose, n=18, 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1556" spread="0.12224"/>
                    <measurement group_id="O2" value="0.1299" spread="0.10015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, pre-dose, n=15, 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1483" spread="0.12563"/>
                    <measurement group_id="O2" value="0.1324" spread="0.10103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, pre-dose, n=15, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1645" spread="0.17438"/>
                    <measurement group_id="O2" value="0.1423" spread="0.13603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, pre-dose, n=15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1446" spread="0.11350"/>
                    <measurement group_id="O2" value="0.1395" spread="0.11754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25,4 weeks post last dose, n=15, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1465" spread="0.12045"/>
                    <measurement group_id="O2" value="0.1402" spread="0.09660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, 4-6 months, n=3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2750" spread="0.15462"/>
                    <measurement group_id="O2" value="0.3908" spread="0.22101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Clinically Relevant Urinalysis Results at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Specific gravity, power of hydrogen (pH), glucose, protein, blood, and ketones were assessed at Weeks (Wk) 1, 2, 5, 9, 13, 17, 21, and 25.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>Specific gravity, power of hydrogen (pH), glucose, protein, blood, and ketones were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. Results for all urinalysis parameters were assessed for clinical relevance.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Clinically Relevant Urinalysis Results at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Specific gravity, power of hydrogen (pH), glucose, protein, blood, and ketones were assessed at Weeks (Wk) 1, 2, 5, 9, 13, 17, 21, and 25.</description>
          <population>Specific gravity, power of hydrogen (pH), glucose, protein, blood, and ketones were assessed at Weeks 1, 2, 5, 9, 13, 17, 21, and 25. Results for all urinalysis parameters were assessed for clinical relevance.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically relevant positive results Wk 1, n=53,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 2, n=46,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 5, n=53,50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 9, n=51,46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 13,n=45,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 17,n=45,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 21,n=42,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant positive results Wk 25,n=39,31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Treatment-emergent Adverse Event (AE) and Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.</description>
        <time_frame>Up to Week 25</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Treatment-emergent Adverse Event (AE) and Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of the Forced Expiratory Volume in 1 Second (FEV1) at Weeks 2, 5, 9, 13, 17, 21, and 25</title>
        <description>FEV1 is defined as the volume of air forcefully expelled from the lungs in one second. FEV1 measurements were taken by spirometry at each clinic visit. FEV1 was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
        <time_frame>Weeks 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>ITT Population: all randomized participants who received at least one dose of study treatment. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of the Forced Expiratory Volume in 1 Second (FEV1) at Weeks 2, 5, 9, 13, 17, 21, and 25</title>
          <description>FEV1 is defined as the volume of air forcefully expelled from the lungs in one second. FEV1 measurements were taken by spirometry at each clinic visit. FEV1 was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
          <population>ITT Population: all randomized participants who received at least one dose of study treatment. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Liters (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="3.14" upper_limit="3.35"/>
                    <measurement group_id="O2" value="3.20" lower_limit="3.10" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="3.23" upper_limit="3.44"/>
                    <measurement group_id="O2" value="3.28" lower_limit="3.17" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=47, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="3.19" upper_limit="3.45"/>
                    <measurement group_id="O2" value="3.23" lower_limit="3.09" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="3.23" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.18" lower_limit="3.06" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="3.18" upper_limit="3.48"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.96" upper_limit="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="3.27" upper_limit="3.54"/>
                    <measurement group_id="O2" value="3.18" lower_limit="3.04" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="3.23" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.18" lower_limit="3.05" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
            <estimate_desc>Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
            <estimate_desc>Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
            <estimate_desc>Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
            <estimate_desc>Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
            <estimate_desc>Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Forced Vital Capacity (FVC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>FVC is defined as the maximum amount of air that can forcibly be blown out after a maximum inspiration. FVC was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Forced Vital Capacity (FVC) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>FVC is defined as the maximum amount of air that can forcibly be blown out after a maximum inspiration. FVC was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
          <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="4.39" upper_limit="4.62"/>
                    <measurement group_id="O2" value="4.45" lower_limit="4.34" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" lower_limit="4.45" upper_limit="4.66"/>
                    <measurement group_id="O2" value="4.49" lower_limit="4.38" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=47, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" lower_limit="4.38" upper_limit="4.66"/>
                    <measurement group_id="O2" value="4.46" lower_limit="4.32" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="4.49" upper_limit="4.75"/>
                    <measurement group_id="O2" value="4.43" lower_limit="4.28" upper_limit="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.43" upper_limit="4.74"/>
                    <measurement group_id="O2" value="4.37" lower_limit="4.19" upper_limit="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" lower_limit="4.51" upper_limit="4.81"/>
                    <measurement group_id="O2" value="4.38" lower_limit="4.22" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.45" upper_limit="4.74"/>
                    <measurement group_id="O2" value="4.41" lower_limit="4.25" upper_limit="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.486</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.384</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
            <estimate_desc>Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak Expiratory Flow Rate (PEFR) at Indicated Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>PEFR is defined as the maximum airflow generated during a forced expiration beginning with the lungs fully inflated. PEFR was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak Expiratory Flow Rate (PEFR) at Indicated Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>PEFR is defined as the maximum airflow generated during a forced expiration beginning with the lungs fully inflated. PEFR was calculated as the maximum of three readings taken at each time point for each participant. Spirometry data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
          <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Liters/minute (L/min)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472.81" lower_limit="455.37" upper_limit="490.25"/>
                    <measurement group_id="O2" value="467.70" lower_limit="449.78" upper_limit="485.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489.08" lower_limit="469.08" upper_limit="509.07"/>
                    <measurement group_id="O2" value="474.53" lower_limit="453.61" upper_limit="495.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=47, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.07" lower_limit="462.19" upper_limit="511.95"/>
                    <measurement group_id="O2" value="478.16" lower_limit="452.57" upper_limit="503.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, n=44, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.04" lower_limit="470.85" upper_limit="517.23"/>
                    <measurement group_id="O2" value="470.81" lower_limit="445.97" upper_limit="495.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493.68" lower_limit="467.67" upper_limit="519.69"/>
                    <measurement group_id="O2" value="455.52" lower_limit="427.15" upper_limit="483.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501.88" lower_limit="476.83" upper_limit="526.93"/>
                    <measurement group_id="O2" value="463.17" lower_limit="435.53" upper_limit="490.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.05" lower_limit="454.31" upper_limit="507.79"/>
                    <measurement group_id="O2" value="466.93" lower_limit="437.33" upper_limit="496.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.686</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.91</ci_lower_limit>
            <ci_upper_limit>30.12</ci_upper_limit>
            <estimate_desc>Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.40</ci_lower_limit>
            <ci_upper_limit>43.50</ci_upper_limit>
            <estimate_desc>Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.622</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.79</ci_lower_limit>
            <ci_upper_limit>44.60</ci_upper_limit>
            <estimate_desc>Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.75</ci_lower_limit>
            <ci_upper_limit>57.22</ci_upper_limit>
            <estimate_desc>Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>38.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>76.66</ci_upper_limit>
            <estimate_desc>Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>38.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>76.02</ci_upper_limit>
            <estimate_desc>Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.484</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.76</ci_lower_limit>
            <ci_upper_limit>54.02</ci_upper_limit>
            <estimate_desc>Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Symptoms Visual Analogue Scale (VAS) Scores at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Participants were asked to indicate on a VAS (0 to 10 centimeters) the severity of four nasal polyposis symptoms (one VAS for each symptom): rhinorrhea; mucus in the throat; nasal blockage; loss of smell. The left-hand side of the scale (0) represents “not troublesome,” and the right hand side of the scale (10) represents “worst possible troublesome.&quot;</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>PP Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Symptoms Visual Analogue Scale (VAS) Scores at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Participants were asked to indicate on a VAS (0 to 10 centimeters) the severity of four nasal polyposis symptoms (one VAS for each symptom): rhinorrhea; mucus in the throat; nasal blockage; loss of smell. The left-hand side of the scale (0) represents “not troublesome,” and the right hand side of the scale (10) represents “worst possible troublesome.&quot;</description>
          <population>PP Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Polyposis, Week 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.51" spread="0.928"/>
                    <measurement group_id="O2" value="8.64" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="1.766"/>
                    <measurement group_id="O2" value="8.47" spread="1.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 5, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="2.310"/>
                    <measurement group_id="O2" value="7.75" spread="2.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 9, n=47, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" spread="3.022"/>
                    <measurement group_id="O2" value="7.74" spread="2.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 13, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.79" spread="3.524"/>
                    <measurement group_id="O2" value="7.21" spread="2.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="3.518"/>
                    <measurement group_id="O2" value="6.44" spread="3.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 21, n=42, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="3.513"/>
                    <measurement group_id="O2" value="6.47" spread="3.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Polyposis, Week 25, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="3.624"/>
                    <measurement group_id="O2" value="6.21" spread="3.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="2.694"/>
                    <measurement group_id="O2" value="6.17" spread="3.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="2.863"/>
                    <measurement group_id="O2" value="6.28" spread="2.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 5, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="3.365"/>
                    <measurement group_id="O2" value="5.98" spread="2.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 9, n=48, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="3.309"/>
                    <measurement group_id="O2" value="6.28" spread="3.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 13, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="3.340"/>
                    <measurement group_id="O2" value="5.19" spread="3.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="3.338"/>
                    <measurement group_id="O2" value="4.82" spread="3.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="3.408"/>
                    <measurement group_id="O2" value="4.70" spread="3.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea, Week 25, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="3.452"/>
                    <measurement group_id="O2" value="4.71" spread="3.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="2.878"/>
                    <measurement group_id="O2" value="6.53" spread="2.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="2.807"/>
                    <measurement group_id="O2" value="6.15" spread="2.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 5, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="3.012"/>
                    <measurement group_id="O2" value="5.92" spread="2.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 9, n=48, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="3.232"/>
                    <measurement group_id="O2" value="6.37" spread="2.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 13, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="3.079"/>
                    <measurement group_id="O2" value="5.49" spread="3.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="3.190"/>
                    <measurement group_id="O2" value="5.16" spread="3.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="3.356"/>
                    <measurement group_id="O2" value="4.84" spread="3.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucus in Throat, Week 25, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="3.298"/>
                    <measurement group_id="O2" value="5.23" spread="3.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" spread="2.459"/>
                    <measurement group_id="O2" value="8.36" spread="1.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41" spread="3.020"/>
                    <measurement group_id="O2" value="7.84" spread="2.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 5, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="3.169"/>
                    <measurement group_id="O2" value="7.33" spread="2.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 9, n=48, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="3.387"/>
                    <measurement group_id="O2" value="7.22" spread="2.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 13, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="3.729"/>
                    <measurement group_id="O2" value="6.27" spread="3.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="3.556"/>
                    <measurement group_id="O2" value="5.71" spread="3.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="3.563"/>
                    <measurement group_id="O2" value="5.77" spread="3.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Blockage, Week 25, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="3.476"/>
                    <measurement group_id="O2" value="5.81" spread="3.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 1, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" spread="1.739"/>
                    <measurement group_id="O2" value="9.22" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 2, n=49, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.79" spread="1.823"/>
                    <measurement group_id="O2" value="9.02" spread="1.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 5, n=49, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.28" spread="2.243"/>
                    <measurement group_id="O2" value="8.69" spread="2.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 9, n=48, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="3.192"/>
                    <measurement group_id="O2" value="8.67" spread="2.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 13, n=45, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="3.296"/>
                    <measurement group_id="O2" value="8.59" spread="2.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="3.648"/>
                    <measurement group_id="O2" value="8.18" spread="2.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 21, n=42, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="3.562"/>
                    <measurement group_id="O2" value="8.20" spread="2.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Smell, Week 25, n=41, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="4.089"/>
                    <measurement group_id="O2" value="7.90" spread="3.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak Nasal Inspiratory Flow (PNIF) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Participants used a portable hand-held inspiratory flow meter to measure and record PNIF in the morning prior to taking the study medication. Three measurements were taken, and the largest measurement was recorded in the electronic diary. PNIF data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak Nasal Inspiratory Flow (PNIF) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Participants used a portable hand-held inspiratory flow meter to measure and record PNIF in the morning prior to taking the study medication. Three measurements were taken, and the largest measurement was recorded in the electronic diary. PNIF data is plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
          <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.82" lower_limit="110.59" upper_limit="131.04"/>
                    <measurement group_id="O2" value="99.66" lower_limit="89.14" upper_limit="110.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.21" lower_limit="116.76" upper_limit="137.66"/>
                    <measurement group_id="O2" value="110.32" lower_limit="99.39" upper_limit="121.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9, n=47, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.91" lower_limit="110.04" upper_limit="137.77"/>
                    <measurement group_id="O2" value="116.71" lower_limit="102.52" upper_limit="130.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, n=45, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.50" lower_limit="123.49" upper_limit="151.51"/>
                    <measurement group_id="O2" value="109.79" lower_limit="94.80" upper_limit="124.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17, n=44, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.41" lower_limit="119.40" upper_limit="145.43"/>
                    <measurement group_id="O2" value="117.02" lower_limit="102.91" upper_limit="131.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21, n=42, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.03" lower_limit="127.13" upper_limit="158.93"/>
                    <measurement group_id="O2" value="113.52" lower_limit="96.28" upper_limit="130.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.02" lower_limit="121.17" upper_limit="152.87"/>
                    <measurement group_id="O2" value="110.37" lower_limit="92.94" upper_limit="127.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.49</ci_lower_limit>
            <ci_upper_limit>35.83</ci_upper_limit>
            <estimate_desc>Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>32.01</ci_upper_limit>
            <estimate_desc>Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.64</ci_lower_limit>
            <ci_upper_limit>27.03</ci_upper_limit>
            <estimate_desc>Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.19</ci_lower_limit>
            <ci_upper_limit>48.23</ci_upper_limit>
            <estimate_desc>Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>34.59</ci_upper_limit>
            <estimate_desc>Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.06</ci_lower_limit>
            <ci_upper_limit>52.96</ci_upper_limit>
            <estimate_desc>Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>26.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.10</ci_lower_limit>
            <ci_upper_limit>50.21</ci_upper_limit>
            <estimate_desc>Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Olfaction Testing: Worst Nostril Score (WNS) and Mean Nostril Score (MNS) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
        <description>Sniffin’Sticks were used to assess each participant’s sense of smell (olfaction). Olfaction testing results were recorded for both the right and left nostrils The worst nostril score (number of correct answers for the worst nostril) and the mean nostril score (mean number of correct answers across both nostrils) were recorded. Scores range from 0 to 12 (high score indicating normal olfactory sensation). Olfaction data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21, and 25</time_frame>
        <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Olfaction Testing: Worst Nostril Score (WNS) and Mean Nostril Score (MNS) at Weeks 1, 2, 5, 9, 13, 17, 21, and 25</title>
          <description>Sniffin’Sticks were used to assess each participant’s sense of smell (olfaction). Olfaction testing results were recorded for both the right and left nostrils The worst nostril score (number of correct answers for the worst nostril) and the mean nostril score (mean number of correct answers across both nostrils) were recorded. Scores range from 0 to 12 (high score indicating normal olfactory sensation). Olfaction data are plotted and analyzed using a repeated measures model to calculate treatment difference, confidence intervals and p-values.</description>
          <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MNS, Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="3.29" upper_limit="4.26"/>
                    <measurement group_id="O2" value="3.68" lower_limit="3.18" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.63" upper_limit="4.78"/>
                    <measurement group_id="O2" value="3.07" lower_limit="2.46" upper_limit="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 9, n=47, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" lower_limit="3.89" upper_limit="5.07"/>
                    <measurement group_id="O2" value="3.69" lower_limit="3.08" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 13, n=45, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" lower_limit="3.75" upper_limit="5.03"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.97" upper_limit="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 17, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="3.93" upper_limit="5.36"/>
                    <measurement group_id="O2" value="4.26" lower_limit="3.45" upper_limit="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 21, n=42, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="3.93" upper_limit="5.61"/>
                    <measurement group_id="O2" value="4.12" lower_limit="3.19" upper_limit="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MNS, Week 25, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" lower_limit="3.61" upper_limit="5.18"/>
                    <measurement group_id="O2" value="3.69" lower_limit="2.81" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 2, n=54, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" lower_limit="2.67" upper_limit="3.69"/>
                    <measurement group_id="O2" value="2.89" lower_limit="2.37" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 5, n=54, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" lower_limit="3.16" upper_limit="4.27"/>
                    <measurement group_id="O2" value="2.41" lower_limit="1.82" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 9, n=47, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="3.21" upper_limit="4.49"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.51" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 13, n=45, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="3.06" upper_limit="4.46"/>
                    <measurement group_id="O2" value="3.14" lower_limit="2.38" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 17, n=43, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="3.15" upper_limit="4.70"/>
                    <measurement group_id="O2" value="3.74" lower_limit="2.87" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 21, n=42, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" lower_limit="3.30" upper_limit="5.02"/>
                    <measurement group_id="O2" value="3.52" lower_limit="2.58" upper_limit="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WNS, Week 25, n=41, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="2.93" upper_limit="4.56"/>
                    <measurement group_id="O2" value="3.30" lower_limit="2.40" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.790</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>MNS, Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>MNS, Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
            <estimate_desc>MNS, Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>MNS, Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.481</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>MNS, Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
            <estimate_desc>MNS, Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
            <estimate_desc>MNS, Week 25</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.444</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>WNS, Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>WNS, Week 5</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>WNS, Week 9</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>WNS, Week 13</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.750</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>WNS, Week 17</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.324</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>WNS, Week 21</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <method>repeated measures model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>WNS, Week 25</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sino-Nasal Outcome Test (SNOT)-22 Questionnaire Total Score at Week 25 (Adjusted for Week 1 Baseline)</title>
        <description>SNOT-22 questionnaire is a modification of the SNOT-20 and contains the questions (ques) related to smell and nasal obstruction. Each ques is graded with a numerical score for each response (res); scores range from 0 for &quot;no symptoms&quot; to 5 for &quot;as bad as things could be.&quot; Scores for each of the ques is summed to derive the total score for that par. at that visit. If the par. did not complete any ques at a visit, then he/she were not to have any missing values imputed, and his/her total score for that visit was set to missing. If a par. had some missing scores (but no more than 50% missing at that visit), then scores for the missing resp were imputed as the mean of the non-missing resp for that par. at that visit. The SNOT-22 total score ranges from 0 to 110, with higher scores representing a worse quality of life. Questionnaire data analysis was done using an ANCOVA to obtain the LS-means, treatment difference and confidence interval at Week 25, adjusting for Week 1 Baseline scores.</description>
        <time_frame>Week 1 and Week 25</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test (SNOT)-22 Questionnaire Total Score at Week 25 (Adjusted for Week 1 Baseline)</title>
          <description>SNOT-22 questionnaire is a modification of the SNOT-20 and contains the questions (ques) related to smell and nasal obstruction. Each ques is graded with a numerical score for each response (res); scores range from 0 for &quot;no symptoms&quot; to 5 for &quot;as bad as things could be.&quot; Scores for each of the ques is summed to derive the total score for that par. at that visit. If the par. did not complete any ques at a visit, then he/she were not to have any missing values imputed, and his/her total score for that visit was set to missing. If a par. had some missing scores (but no more than 50% missing at that visit), then scores for the missing resp were imputed as the mean of the non-missing resp for that par. at that visit. The SNOT-22 total score ranges from 0 to 110, with higher scores representing a worse quality of life. Questionnaire data analysis was done using an ANCOVA to obtain the LS-means, treatment difference and confidence interval at Week 25, adjusting for Week 1 Baseline scores.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.13" spread="2.96"/>
                    <measurement group_id="O2" value="40.36" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mixed effects model</param_type>
            <param_value>-13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.2</ci_lower_limit>
            <ci_upper_limit>-4.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index Score of the EuroQoL Quality of Life-5D (EQ-5D) Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</title>
        <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The first part contains descriptions of the following five components: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to each of the five domains are measured on a 3-point scale (1-no problems, 2-some problems, and 3-severe problems). An index for the descriptive scores was derived using the general European weights, obtained for each of the countries in this study. Index scores were derived for each participant at each time point. ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
        <time_frame>Week 1 and Week 25</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Index Score of the EuroQoL Quality of Life-5D (EQ-5D) Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</title>
          <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The first part contains descriptions of the following five components: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to each of the five domains are measured on a 3-point scale (1-no problems, 2-some problems, and 3-severe problems). An index for the descriptive scores was derived using the general European weights, obtained for each of the countries in this study. Index scores were derived for each participant at each time point. ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.02"/>
                    <measurement group_id="O2" value="0.91" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score of the EQ-5D Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</title>
        <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The second part of the questionnaire is a VAS question, requiring the participant to self rate his/her health score on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
        <time_frame>Week 1 and Week 25</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score of the EQ-5D Questionnaire at Week 25 (Adjusting for Week 1 Baseline Scores)</title>
          <description>The EQ-5D is a standardized, 2-part questionnaire used to measure health outcomes. The second part of the questionnaire is a VAS question, requiring the participant to self rate his/her health score on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). ANCOVA model with treatment, Baseline (Week 1 scores) and country as factors was used to calculate treatment difference and confidence intervals at Week 25.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.13" spread="2.30"/>
                    <measurement group_id="O2" value="75.45" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>12.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance at Weeks 1, 2, 5, 9, 13, and 25</title>
        <description>Blood samples were collected for the assessment of systemic clearance at Weeks 1, 2, 5, 9, 13, and 25. Systemic Clearance (CL) is estimated using a population-Pharmacokinetic model incorporating all available data points from all subjects. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>Pharmacokinetic (PK) Population: participants in the Safety Population for whom at least one PK sample was obtained and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance at Weeks 1, 2, 5, 9, 13, and 25</title>
          <description>Blood samples were collected for the assessment of systemic clearance at Weeks 1, 2, 5, 9, 13, and 25. Systemic Clearance (CL) is estimated using a population-Pharmacokinetic model incorporating all available data points from all subjects. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>Pharmacokinetic (PK) Population: participants in the Safety Population for whom at least one PK sample was obtained and analyzed.</population>
          <units>Liters per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" spread="0.0659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Weeks 1, 2, 5, 9, 13, and 25</title>
        <description>Volume of distribution at steady-state was derived from pharmacokinetic parameter estimates of a population pharmacokinetic model. Blood samples were collected for analysis of volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. All available concentrations at all available datapoints from all participants were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Weeks 1, 2, 5, 9, 13, and 25</title>
          <description>Volume of distribution at steady-state was derived from pharmacokinetic parameter estimates of a population pharmacokinetic model. Blood samples were collected for analysis of volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. All available concentrations at all available datapoints from all participants were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.387" spread="2.0062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bodyweight-adjusted Clearance</title>
        <description>Clearance is the volume of plasma that would contain the amount of drug excreted per day. Blood samples were collected for the assessment of bodyweight-adjusted clearance at Weeks 1, 2, 5, 9, 13, and 25. Clearance was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Bodyweight-adjusted Clearance</title>
          <description>Clearance is the volume of plasma that would contain the amount of drug excreted per day. Blood samples were collected for the assessment of bodyweight-adjusted clearance at Weeks 1, 2, 5, 9, 13, and 25. Clearance was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Liters per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2170" spread="0.009547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-State Volume of Distribution</title>
        <description>Steady-state volume of distribution is the blood and tissue volume into which a drug is distributed and the relative binding of drug to protein in these spaces. Blood samples were collected for the assessment of steady-state volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. Steady-state volume of distribution was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-State Volume of Distribution</title>
          <description>Steady-state volume of distribution is the blood and tissue volume into which a drug is distributed and the relative binding of drug to protein in these spaces. Blood samples were collected for the assessment of steady-state volume of distribution at Weeks 1, 2, 5, 9, 13, and 25. Steady-state volume of distribution was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0958" spread="0.3226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Drug Concentration (Cmax), Average Concentration (Cav[0-inf]), and Steady State Maximum Observed Plasma Drug Concentration (Cmax SS)</title>
        <description>Blood samples were collected for the assessment of Cmax, Cav(0-inf), and Cmax SS at Weeks 1, 2, 5, 9, 13, and 25. These parameters were estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Drug Concentration (Cmax), Average Concentration (Cav[0-inf]), and Steady State Maximum Observed Plasma Drug Concentration (Cmax SS)</title>
          <description>Blood samples were collected for the assessment of Cmax, Cav(0-inf), and Cmax SS at Weeks 1, 2, 5, 9, 13, and 25. These parameters were estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Micrograms per milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.22" spread="7.8536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cav(0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.45" spread="5.4324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax SS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.40" spread="10.3703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Drug Concentration Versus Time Curve From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
        <description>Blood samples were scheduled to be collected for the assessment of AUC(0-inf) at Weeks 1, 2, 5, 9, 13, and 25 AUC[0-inf] is derived from individual systemic clearance estimates using the expression AUC[0-inf] = Dose/CL. Hence all data are incorporated into the estimation of CL and by implication AUC[0-inf]. The actual time range over which pharmacokinetic data were collected was from time 0 to 336 days post first dose.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Drug Concentration Versus Time Curve From Time 0 Extrapolated to Infinite Time (AUC[0-inf])</title>
          <description>Blood samples were scheduled to be collected for the assessment of AUC(0-inf) at Weeks 1, 2, 5, 9, 13, and 25 AUC[0-inf] is derived from individual systemic clearance estimates using the expression AUC[0-inf] = Dose/CL. Hence all data are incorporated into the estimation of CL and by implication AUC[0-inf]. The actual time range over which pharmacokinetic data were collected was from time 0 to 336 days post first dose.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Microgram.day per milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3456.69" spread="152.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (Alpha) and Half-life (Beta)</title>
        <description>Half-life (Alpha) is the rate of decline in plasma concentrations due to the process of drug redistribution from the central to the peripheral compartment and half-life (Beta ) is the rate of decline due to the process of drug elimination due to metabolism. Blood samples were collected for the assessment of half-life (Alpha) and half-life (Beta) at Weeks 1, 2, 5, 9, 13, and 25. Half-life was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (Alpha) and Half-life (Beta)</title>
          <description>Half-life (Alpha) is the rate of decline in plasma concentrations due to the process of drug redistribution from the central to the peripheral compartment and half-life (Beta ) is the rate of decline due to the process of drug elimination due to metabolism. Blood samples were collected for the assessment of half-life (Alpha) and half-life (Beta) at Weeks 1, 2, 5, 9, 13, and 25. Half-life was estimated using a population-pharmacokinetic model incorporating all available data points from all participants. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Half-life (Alpha)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5456" spread="0.4108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Half-life (Beta)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1258" spread="1.0250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic/Pharmacodynamic (PK/PD) Model Derived Baseline</title>
        <description>Blood samples were collected for the assessment of PK/PD model derived Baseline at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available blood eosinophil count data were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic/Pharmacodynamic (PK/PD) Model Derived Baseline</title>
          <description>Blood samples were collected for the assessment of PK/PD model derived Baseline at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available blood eosinophil count data were incorporated into the model. Individual values were estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Giga units per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4231" spread="0.02873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK/PD Model Derived Coefficient of Variation of Baseline (CV[Baseline]), Variation of Maximal Effect of Drug (CV[Emax]), and Residual</title>
        <description>A residual is the difference between the observed and predicted values. Blood samples were collected for the assessment of PK/PD model derived CV(Baseline), CV(Emax), and residual at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated subjects). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>PK/PD Model Derived Coefficient of Variation of Baseline (CV[Baseline]), Variation of Maximal Effect of Drug (CV[Emax]), and Residual</title>
          <description>A residual is the difference between the observed and predicted values. Blood samples were collected for the assessment of PK/PD model derived CV(Baseline), CV(Emax), and residual at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated subjects). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percentage of variation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV(Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9951" spread="6.5318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV(Emax)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8910" spread="6.6193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Residual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3787" spread="1.3763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK/PD Model Derived Half Maximal Effective Drug Concentration (EC50)</title>
        <description>Blood samples were collected for the assessment of PK/PD model derived EC50 at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-partcipant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>PK/PD Model Derived Half Maximal Effective Drug Concentration (EC50)</title>
          <description>Blood samples were collected for the assessment of PK/PD model derived EC50 at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-partcipant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Microgram per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4303" spread="0.4404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK/PD Model Derived Maximum Inhibition</title>
        <description>Blood samples were collected for the assessment of Maximum Inhibition at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
        <time_frame>Weeks 1, 2, 5, 9, 13, 17, 21 and 25</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>PK/PD Model Derived Maximum Inhibition</title>
          <description>Blood samples were collected for the assessment of Maximum Inhibition at Weeks 1, 2, 5, 9, 13, 17, 21 and 25. An exploratory Emax direct response model was fitted to serial blood eosinophil count data (including placebo) using model-predicted mepolizumab concentrations (with zero imputed for placebo treated participants). All available datapoints were incorporated into the model. Individual values are estimated from the model as post-hoc values after incorporating between-participant variability.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percentage of inhibition</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0748" spread="1.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Immunogenicity (Anti-mepolizumab Antibody Testing)</title>
        <description>Blood samples were collected at Weeks 1, 5, 13, and 25 for anti-mepolizumab antibody testing.</description>
        <time_frame>Weeks 1, 5, 13, and 25</time_frame>
        <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepolizumab 750 mg</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Immunogenicity (Anti-mepolizumab Antibody Testing)</title>
          <description>Blood samples were collected at Weeks 1, 5, 13, and 25 for anti-mepolizumab antibody testing.</description>
          <population>ITT Population. Only those participants available at the specified time points (represented by n=X, X) were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, pre-dose, n=53, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5, pre-dose, n=53, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, pre-dose, n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13, 4-6 months, n=1, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, 4-6 months, n=25, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25, study exit, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the first dose of flixonase administration (at the start of the Run-in Period) up to the end of the study (up to 11 months).</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all enrolled participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mepolizumab 750 mg</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of mepolizumab 750 milligrams (mg) by intravenous infusion</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received up to a total of six doses (one every 4 weeks) of matching placebo by intravenous infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Part B was removed due to the low numbers of participants enrolling into Part B. GSK determined it was no longer feasible to achieve a meaningful number of participants and therefore recruitment into this portion of the study was stopped.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

